Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer
Status:
Terminated
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest safe dose of intraperitoneal
tgDCC-E1A that can be given in combination with paclitaxel as a treatment for patients with
recurrent, platinum-resistant ovarian cancer. How the cancer responds to this treatment will
also be studied. Researchers will also ask the patients if they will allow additional tumor
samples to be collected and extra blood samples to be drawn. These samples will be used to
learn about the biological response before and after treatment.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
National Cancer Institute (NCI) National Institutes of Health (NIH)